Carmot’s chance of beating the odds in the biotech market just ended
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with a special thanks to everyone who joined us for STAT’s live event in New York City last night. Today we have a sober look at the future of mRNA, a plot to bring CAR-T back to its founding ideals, and the downside of a billion-dollar buyout.
Read Original Article: Carmot’s chance of beating the odds in the biotech market just ended »
